Numerous studies indicate that Sirtuin 1 (SIRT1), a mammalian nicotinamide adenine dinucleotide (NAD + )-dependent histone deacetylase (HDAC), plays a crucial role in p53-mediated stress responses by deacetylating p53. Nevertheless, the acetylation levels of p53 are dramatically increased upon DNA damage, and it is not well understood how the SIRT1-p53 interaction is regulated during the stress responses. Here, we identified Set7/9 as a unique regulator of SIRT1. SIRT1 interacts with Set7/9 both in vitro and in vivo. In response to DNA damage in human cells, the interaction between Set7/9 and SIRT1 is significantly enhanced and coincident with an increase in p53 acetylation levels. Importantly, the interaction of SIRT1 and p53 is strongly suppressed in the presence of Set7/9. Consequently, SIRT1-mediated deacetylation of p53 is abrogated by Set7/9, and p53-mediated transactivation is increased during the DNA damage response. Of note, whereas SIRT1 can be methylated at multiple sites within its N terminus by Set7/9, a methylation-defective mutant of SIRT1 still retains its ability to inhibit p53 activity. Taken together, our results reveal that Set7/9 is a critical regulator of the SIRT1-p53 interaction and suggest that Set7/9 can modulate p53 function indirectly in addition to acting through a methylation-dependent mechanism. T he class III HDAC sirtuins, SIRT1 to SIRT7, are homologous to yeast silent information regulator 2 (Sir2) and play important biological roles during aging, metabolism, and autophagy (1, 2). Within the sirtuins, SIRT1 is the closest homolog of yeast Sir2. In contrast to class I and II HDACs, sirtuins require nicotinamide adenine dinucleotide (NAD + ) as a coenzyme to act on their target proteins (3). Numerous studies have also suggested a role for SIRT1 in the development of tumors because SIRT1 is up-regulated in various cancerous tissues and cell lines, such as leukemia and prostate cancer (4, 5). In addition, SIRT1 is overexpressed in several p53-deficient tumor cell lines, and the transient knockdown of SIRT1 leads to increased apoptosis after DNA damage or oxidative stress (6). Moreover, tumor suppressors such as p53 (7,8) and FoxO (9,10) are deacetylated by SIRT1 and, thus, inactivated in response to DNA damage, which provides further evidence that SIRT1 is an oncogenic protein.The tumor suppressor hypermethylated in cancer 1 (HIC1) has been shown to inhibit SIRT1 expression by forming a repressive complex with SIRT1 on its own promoter and sensitizing the p53 response to DNA damage (11). In addition, deleted in breast cancer 1 (DBC1) has also been reported to be a negative repressor of SIRT1 in various cell lines and leads to increased levels of p53 acetylation and up-regulation of p53 transcriptional activities (12, 13). However, active regulator of SIRT1 (AROS) interacts with SIRT1 and activates its deacetylase activity (14). In addition to protein interactions, posttranslational modifications of SIRT1 are also important for its activity. For instance, SIRT1 is phosphorylated by J...